Characteristics and outcomes of gemcitabine-associated pulmonary hypertension - Hypertension pulmonaire : physiopathologie et innovation thérapeutique
Journal Articles ERJ Open Research Year : 2024

Characteristics and outcomes of gemcitabine-associated pulmonary hypertension

Abstract

Background Despite its known cardiac and lung toxicities, the chemotherapy drug gemcitabine has only rarely been associated with pulmonary hypertension (PH), and the underlying mechanism remains unclear. The objective of the present study was to assess the association between gemcitabine and PH. Methods We identified incident cases of precapillary PH confirmed by right heart catheterisation in patients treated with gemcitabine from the French PH Registry between January 2007 and December 2022. The aetiology, clinical, functional, radiological and haemodynamic characteristics of PH were reviewed at baseline and during follow-up. A pharmacovigilance disproportionality analysis was conducted using the World Health Organization (WHO) pharmacovigilance database. Results We identified nine cases of pulmonary arterial hypertension, either induced (in eight patients) or exacerbated (in one patient) by gemcitabine. Patients exhibited severe precapillary PH, with a median mean pulmonary arterial pressure of 40 (range 26–47) mmHg, a cardiac index of 2.4 (1.6–3.9) L·min −1 ·m −2 and a pulmonary vascular resistance of 6.3 (3.1–12.6) Wood units. The median time from the initiation of gemcitabine to the onset of PH was 7 (4–50) months, with patients receiving a median of 16 (6–24) gemcitabine injections. Six patients showed clinical improvement upon discontinuation of gemcitabine. In the WHO pharmacovigilance database, we identified a significant signal with 109 cases reporting at least one adverse event related to PH with gemcitabine. Conclusion Both clinical cases and pharmacovigilance data substantiate a significant association between gemcitabine use and the onset or worsening of precapillary PH. The observed improvement following the discontinuation of treatment underscores the importance of PH screening in gemcitabine-exposed patients experiencing unexplained dyspnoea.
Fichier principal
Vignette du fichier
mouillot_2024_vol10_11_erj_open_res.pdf (6.63 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive
licence

Dates and versions

hal-04666846 , version 1 (02-08-2024)

Licence

Identifiers

Cite

Pierre Mouillot, Nicolas Favrolt, Charles Khouri, Aurélie Grandvuillemin, Marie-Camille Chaumais, et al.. Characteristics and outcomes of gemcitabine-associated pulmonary hypertension. ERJ Open Research, 2024, 10 (3), pp.00654-2023. ⟨10.1183/23120541.00654-2023⟩. ⟨hal-04666846⟩
75 View
8 Download

Altmetric

Share

More